Cite
HARVARD Citation
Chen, I. et al. (n.d.). 776TiPPACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Annals of oncology. p. . [Online].